As semaglutide patents begin expiring and generic manufacturers in India and China gear up for mass production, the global...
As semaglutide patents begin expiring across key markets, the real disruption isn't Novo Nordisk losing revenue — it's that...
Semaglutide's patent expiration isn't a future problem for GLP-1 manufacturers — it's an active restructuring of the global obesity...
Wegovy HD's FDA approval at 7.2 mg delivers 20.7% mean weight loss — but the real story isn't the...
Hims & Hers posted its best weekly stock gain after announcing a deal with Novo Nordisk, and Wall Street...
